TMS Side Effects: What Patients Actually Experience

Transcranial magnetic stimulation is one of the best-tolerated neuromodulation therapies in routine clinical use. Most patients experience only mild, transient scalp discomfort at the treatment site; the rare serious event — seizure — is estimated at fewer than 1 in 60,000 sessions when published safety guidelines are followed.¹² There is no sedation, no systemic drug exposure, and no documented cognitive impairment at FDA-cleared parameters. This article walks through what patients actually report during and after sessions, the rare serious adverse event in numerical terms, the common worries that are not in fact risks, and when to call the clinic. It is patient and family literacy — not a substitute for the clinical consultation, which determines candidacy and parameter selection.

The common side effects — typically mild, typically self-limited

The side effects observed at any meaningful frequency in clinical use are local and short-lived. The canonical real-world tolerability data come from the Janicak 2008 acute and extended-exposure safety analysis and the Carpenter 2012 multisite naturalistic study; both describe a side-effect profile dominated by sensations at the treatment site rather than systemic effects.³⁴

Scalp discomfort at the treatment site. The most frequently reported sensation is a tapping, pressure, or tingling feeling under the coil, occasionally sharper during the first few seconds of stimulation. The sensation is the direct result of magnetic activation of cutaneous and superficial nerve fibers in the scalp — not of any tissue injury. Most patients accommodate within three to five sessions; where tolerability is limiting, the treating clinician can slowly ramp stimulation intensity over the opening sessions.⁵

Treatment-site headache. Mild headache, usually localized to the area near the coil, is the second most common side effect and is generally responsive to standard over-the-counter analgesics. Frequency and intensity decline meaningfully across the course as scalp accommodation develops.³

Facial twitching or contraction near the eye or jaw. Visible muscle contraction during the pulse train — typically near the temple, the corner of the eye, or the masseter — reflects activation of superficial motor nerves under the coil. It is not harmful and stops the moment the pulse stops. It is one of the more startling sensations on the first day; it is also one of the first to feel routine.

Lightheadedness. Transient lightheadedness, usually related to position change at session start or end, is occasionally reported. Patients are typically advised to remain seated briefly after the session before standing.

Less common but documented effects

A second tier of effects is described in the safety literature at lower frequency:

• Auditory discomfort. The coil produces a sharp click at close range; cumulative exposure across a 36-session course can produce transient threshold shifts if hearing protection is omitted. Earplugs are worn during every session.²
• Sleep changes. More often improvement than disturbance — better sleep is a recognized early antidepressant signal. A minority of patients report transient initial insomnia in the opening weeks.
• Mood activation. TMS can occasionally produce a brief mood lift or activation in the days before sustained antidepressant response sets in. Patients with bipolar features or a personal or family history of mania are screened and monitored accordingly; this is part of the candidacy safety screen rather than a typical course expectation.

None of these are reasons to interrupt treatment in routine cases. They are reasons to keep the treating clinician informed.

The serious adverse event: seizure, in numerical terms

The single adverse event that anchors the safety conversation is provoked seizure during stimulation. The contemporary estimate, drawn from the Lerner 2019 multi-clinic survey and codified in the Rossi 2021 safety guidelines, is fewer than 1 seizure per 60,000 sessions when published parameter and screening guidelines are followed.¹² Older figures sometimes still circulate — the Rossi 2009 guidelines estimated approximately 1 per 30,000 sessions — but the current safety framework, with refined intensity ceilings and tightened screening, has measurably lowered incidence.⁶

Risk factors that elevate baseline seizure susceptibility, and which the pre-treatment screen is specifically designed to detect:

• A personal history of seizure or seizure disorder — the single largest risk factor.
• Active alcohol or sedative withdrawal.
• Medications that lower seizure threshold — most notably bupropion at the higher end of the therapeutic range, tramadol, certain antipsychotics, and stimulants in high dose.
• Acute sleep deprivation.
• Significant structural brain lesion in the treatment field.

The candidacy safety screen — covered in detail in our article on TMS candidacy and contraindications — is the reason most patients with elevated baseline risk are identified before the first session rather than during one. In the rare event a seizure occurs during a session, clinic protocol calls for immediate stimulation cessation, supportive care, and 911 transport. The published case literature is consistent: TMS-provoked seizures in this setting are typically single, self-limited, and do not progress to a chronic seizure disorder.¹²

This is the part of the side-effect conversation where patients most often want a number rather than a reassurance. The number is the one above.

What TMS does not cause

A second category of patient worries needs to be addressed plainly because it dominates the consult-room conversation and is reliably confused with other treatments.

Memory loss and cognitive impairment. There is no documented memory or cognitive impairment from rTMS delivered at FDA-cleared parameters. The Janicak 2008 acute and extended-exposure analysis and the Carpenter 2012 real-world dataset both report neurocognitive measures unchanged or modestly improved across a treatment course.³⁴ The most common source of the worry is conflation with electroconvulsive therapy (ECT), which can produce transient anterograde and retrograde memory effects. TMS and ECT are different treatments — different mechanism, different delivery, different side-effect profile. The candidacy article above details the distinction; for present purposes, the relevant point is that the memory-effect literature belongs to ECT, not to TMS.

Personality change. No. The DLPFC is the cortical target; antidepressant response, when it occurs, is a return toward baseline function rather than a change in personality.

Permanent neurological damage. No. Cumulative-exposure analyses across thousands of patient-years of clinical use have not identified persistent neurological deficits attributable to rTMS at cleared parameters.³

Hair loss at the treatment site. No. The magnetic field does not affect hair follicles.

Brain tumor, cancer, or radiation exposure. No. TMS uses a magnetic field, not ionizing radiation. No X-rays, no gamma rays, no radioisotopes. The induced electrical current is confined to a focal region of cortex approximately 2 to 3 cm in diameter under the coil and ceases the moment the pulse stops.

Tolerability across the course

The clinically useful pattern, observed across both pivotal trials and naturalistic datasets, is that side effects are front-loaded.³⁴ Scalp discomfort, treatment-site headache, and facial contraction are most prominent in the first five to seven sessions and decline substantially across the first one to two weeks as the scalp accommodates. Patients who tolerate the opening week almost always tolerate the rest of the course. Discontinuation for side-effect intolerance is uncommon in routine clinical practice; the Carpenter 2012 multisite series places it in the low single digits.⁴

This is the empirical answer to the question patients most often phrase as "Will it get worse?" The data say the opposite.

A brief comparison to oral antidepressant side effects

The framing that often helps in consultation is not "TMS has fewer side effects than medication" — which is reductive — but that the profiles are categorically different. Selective serotonin and serotonin-norepinephrine reuptake inhibitors produce systemic effects because they act systemically: gastrointestinal symptoms, sexual side effects, weight change, fatigue, and emotional blunting are documented at meaningful frequency across the class. TMS effects are local to the scalp site and self-limited to the session and the hours after. Neither profile is universally preferable; many patients are on both modalities concurrently, which is consistent with how most insurance policies frame TMS — as an addition to, not a replacement for, pharmacotherapy.

When to call the clinic

Patients in active treatment are advised to contact the clinic the same day for any of the following: a new-onset severe or unusually persistent headache, any seizure-like event or loss of awareness, a sudden worsening of mood or new suicidal ideation, or any symptom the patient or family judges concerning. The clinic responds same-day to clinical concerns during the active course. This is general clinical guidance, not individualized medical advice — patients with specific concerns should speak with the treating clinician.

Key takeaways

• The dominant side effect of TMS is mild, self-limited scalp discomfort at the treatment site, typically accommodating within the first one to two weeks of treatment.³⁴
• Treatment-site headache is the second most common effect and is generally responsive to standard over-the-counter analgesics.³
• The rare serious adverse event — provoked seizure — is estimated at fewer than 1 in 60,000 sessions when published safety guidelines are followed.¹²
• TMS does not cause memory loss, personality change, hair loss, or radiation exposure; the most common confusion is with ECT, which is a different treatment.³
• Side effects are front-loaded: patients who tolerate the opening week of treatment almost always tolerate the rest of the course.⁴
• Same-day contact with the clinic is appropriate for new-onset severe headache, any seizure-like event, mood crisis, or any symptom the patient or family judges concerning.

For patients across Anaheim, Orange County, and the broader 30-mile radius who want a clinician's read on whether the tolerability profile of TMS therapy fits their treatment history and medication list, the candidacy consultation answers that question directly. Most patients begin by verifying insurance coverage so the clinical and financial picture is clear before scheduling; the safety screen is built into the same consultation.

Sources / Further reading